Warning: The NCBI web site requires JavaScript to function. more...
Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science study.
Tat SK, Pelletier JP, Vergés J, Lajeunesse D, Montell E, Fahmi H, Lavigne M, Martel-Pelletier J.
Arthritis Res Ther. 2007;9(6):R117.
Related citations
The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells.
Kwan Tat S, Pelletier JP, Lajeunesse D, Fahmi H, Lavigne M, Martel-Pelletier J.
Clin Exp Rheumatol. 2008 Mar-Apr;26(2):295-304.
Proteinase-activated receptor (PAR)-2 activation impacts bone resorptive properties of human osteoarthritic subchondral bone osteoblasts.
Amiable N, Tat SK, Lajeunesse D, Duval N, Pelletier JP, Martel-Pelletier J, Boileau C.
Bone. 2009 Jun;44(6):1143-50. Epub 2009 Mar 2.
Differential modulation of RANKL isoforms by human osteoarthritic subchondral bone osteoblasts: influence of osteotropic factors.
Tat SK, Pelletier JP, Lajeunesse D, Fahmi H, Duval N, Martel-Pelletier J.
Bone. 2008 Aug;43(2):284-91. Epub 2008 Apr 26.
Diacerein reduces the excess synthesis of bone remodeling factors by human osteoblast cells from osteoarthritic subchondral bone.
Pelletier JP, Lajeunesse D, Reboul P, Mineau F, Fernandes JC, Sabouret P, Martel-Pelletier J.
J Rheumatol. 2001 Apr;28(4):814-24.
Strontium ranelate inhibits key factors affecting bone remodeling in human osteoarthritic subchondral bone osteoblasts.
Tat SK, Pelletier JP, Mineau F, Caron J, Martel-Pelletier J.
Bone. 2011 Sep;49(3):559-67. Epub 2011 Jun 12.
Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts.
Yonou H, Horiguchi Y, Ohno Y, Namiki K, Yoshioka K, Ohori M, Hatano T, Tachibana M.
Prostate. 2007 Jun 1;67(8):840-8.
The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts.
Enjuanes A, Ruiz-Gaspà S, Peris P, Ozalla D, Álvarez L, Combalia A, Martínez de Osaba MJ, Monegal A, Pares A, Guañabens N.
Endocrine. 2010 Feb;37(1):180-6. Epub 2009 Nov 24.
Osteoblast-like cells from human subchondral osteoarthritic bone demonstrate an altered phenotype in vitro: possible role in subchondral bone sclerosis.
Hilal G, Martel-Pelletier J, Pelletier JP, Ranger P, Lajeunesse D.
Arthritis Rheum. 1998 May;41(5):891-9.
RANKL/OPG in primary cultures of osteoblasts from post-menopausal women. Differences between osteoporotic hip fractures and osteoarthritis.
Giner M, Rios MA, Montoya MA, Vázquez MA, Naji L, Pérez-Cano R.
J Steroid Biochem Mol Biol. 2009 Jan;113(1-2):46-51. Epub 2008 Nov 27.
Prolactin decreases the expression ratio of receptor activator of nuclear factor kappaB ligand/osteoprotegerin in human fetal osteoblast cells.
Seriwatanachai D, Charoenphandhu N, Suthiphongchai T, Krishnamra N.
Cell Biol Int. 2008 Sep;32(9):1126-35. Epub 2008 May 9.
Effects on osteoclast and osteoblast activities in cultured mouse calvarial bones by synovial fluids from patients with a loose joint prosthesis and from osteoarthritis patients.
Andersson MK, Lundberg P, Ohlin A, Perry MJ, Lie A, Stark A, Lerner UH.
Arthritis Res Ther. 2007;9(1):R18.
Enjuanes A, Ruiz-Gaspà S, Peris P, Ozalla D, Alvarez L, Combalia A, Martínez de Osaba MJ, Monegal A, Pares A, Guañabens N.
Endocrine. 2010 Apr;37(2):322-8. Epub 2010 Jan 7.
New perspective in osteoarthritis: the OPG and RANKL system as a potential therapeutic target?
Tat SK, Pelletier JP, Velasco CR, Padrines M, Martel-Pelletier J.
Keio J Med. 2009 Mar;58(1):29-40. Review.
Modifying RANKL/OPG mRNA expression in differentiating and growing human primary osteoblasts.
Giner M, Montoya MJ, Vázquez MA, Rios MJ, Moruno R, Miranda MJ, Pérez-Cano R.
Horm Metab Res. 2008 Dec;40(12):869-74. Epub 2008 Oct 17.
Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma.
Qiang YW, Chen Y, Stephens O, Brown N, Chen B, Epstein J, Barlogie B, Shaughnessy JD Jr.
Blood. 2008 Jul 1;112(1):196-207. Epub 2008 Feb 27.
Modulation of OPG, RANK and RANKL by human chondrocytes and their implication during osteoarthritis.
Kwan Tat S, Amiable N, Pelletier JP, Boileau C, Lajeunesse D, Duval N, Martel-Pelletier J.
Rheumatology (Oxford). 2009 Dec;48(12):1482-90. Epub 2009 Sep 17.
Alendronate and raloxifene affect the osteoprotegerin/RANKL system in human osteoblast primary cultures from patients with osteoporosis and osteoarthritis.
Giner M, Rios MJ, Montoya MJ, Vázquez MA, Miranda C, Pérez-Cano R.
Eur J Pharmacol. 2011 Jan 15;650(2-3):682-7. Epub 2010 Nov 2.
Nonsteroidal antiinflammatory drugs and prostaglandin E(2) modulate the synthesis of osteoprotegerin and RANKL in the cartilage of patients with severe knee osteoarthritis.
Moreno-Rubio J, Herrero-Beaumont G, Tardio L, Alvarez-Soria MA, Largo R.
Arthritis Rheum. 2010 Feb;62(2):478-88.
Long wave ultrasound may enhance bone regeneration by altering OPG/RANKL ratio in human osteoblast-like cells.
Maddi A, Hai H, Ong ST, Sharp L, Harris M, Meghji S.
Bone. 2006 Aug;39(2):283-8. Epub 2006 Mar 29.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on